Gastric emptying and glycaemia in health and diabetes mellitus

Nature Reviews Endocrinology

Volumn 11, Issue 2, 2015, Pages 112-128

  Phillips, Liza K ^a   Deane, Adam M ^a   Jones, Karen L ^a   Rayner, Chris K ^a   Horowitz, Michael ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIEMETIC AGENT; BOTULINUM TOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; PRAMLINTIDE; PROKINETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT;

CLINICAL FEATURE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INCIDENCE; INTERSTITIAL CELL OF CAJAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PREVALENCE; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; STOMACH PARESIS; DRUG EFFECTS; HYPERGLYCEMIA; PHYSIOLOGY;

GASTRIC EMPTYING; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD;

EID: 84923079981     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.202     Document Type: Review

References (208)

1. Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007).
2. Little, T. J. et al. The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed. Am. J. Physiol. Endocrinol. Metab. 291, E647-E655 (2006).
3. Trahair, L. G. et al. Comparative effects of variations in duodenal glucose load on glycemic, insulinemic, and incretin responses in healthy young and older subjects. J. Clin. Endocrinol. Metab. 97, 844-851 (2012).
4. Marathe, C. S., Rayner, C. K., Jones, K. L. & Horowitz, M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 36, 1396-1405 (2013).
5. Chang, J., Rayner, C. K., Jones, K. L. & Horowitz, M. Diabetic gastroparesis and its impact on glycemia. Endocrinol. Metab. Clin. North Am. 39, 745-762 (2010).
6. Stevens, J. E., Jones, K. L., Rayner, C. K. & Horowitz, M. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. Expert Opin. Pharmacother 14, 1171-1186 (2013).
7. Horowitz, M. & Dent, J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillière's Clin. Gastroenterol. 5, 371-407 (1991).
8. Vittal, H., Farrugia, G., Gomez, G. & Pasricha, P. J. Mechanisms of disease: the pathological basis of gastroparesis - a review of experimental and clinical studies. Nat. Clin. Pract. Gastroenterol. Hepatol. 4, 336-346 (2007).
9. Code, C. F. & Marlett, J. A. The interdigestive myo-electric complex of the stomach and small bowel of dogs. J. Physiol. 246, 289-309 (1975).
10. Vantrappen, G., Janssens, J., Hellemans, J. & Ghoos, Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J. Clin. Invest. 59, 1158-1166 (1977).
11. Sarna, S. K. Cyclic motor activity; migrating motor complex: 1985. Gastroenterology 89, 894-913 (1985).
12. Lin, Z. et al. Association of the status of interstitial cells of Cajal and electrogastrogram parameters, gastric emptying and symptoms in patients with gastroparesis. Neurogastroenterol. Motil. 22, 56-61, e10 (2010).
13. Farrugia, G. Interstitial cells of Cajal in health and disease. Neurogastroenterol. Motil. 20 (Suppl, 1), 54-63 (2008).
14. Ohno, T., Mochiki, E. & Kuwano, H. The roles of motilin and ghrelin in gastrointestinal motility. Int. J. Pept. 2010, 820794 (2010).
15. Ariga, H. et al. Endogenous acyl ghrelin is involved in mediating spontaneous phase III-like contractions of the rat stomach. Neurogastroenterol. Motil. 19, 675-680 (2007).
16. Tack, J. et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 55, 327-333 (2006).
17. Gentilcore, D. et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J. Clin. Endocrinol. Metab. 91, 2062-2067 (2006).
18. Wang, Y. R., Fisher, R. S. & Parkman, H. P. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am. J. Gastroenterol. 103, 313-322 (2008).
19. Bharucha, A. E., Camilleri, M., Forstrom, L. A. & Zinsmeister, A. R. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin. Endocrinol. (Oxf.) 70, 415-420 (2009).
20. Horowitz, M. et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur. J. Nucl. Med. 18, 229-234 (1991).
21. Jones, K. L. et al. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J. Nucl. Med. 36, 2220-2228 (1995).
22. Jones, K. L. et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 24, 1264-1269 (2001).
23. Jung, H. K. et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 136, 1225-1233 (2009).
24. [No authors listed] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977-986 (1993).
25. [No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853 (1998).
26. Rayner, C. K., Samsom, M., Jones, K. L. & Horowitz, M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 24, 371-381 (2001).
27. Samsom, M. et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care 26, 3116-3122 (2003).
28. Ariga, H. et al. Does ghrelin explain accelerated gastric emptying in the early stages of diabetes mellitus? Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R1807-R1812 (2008).
29. Schwartz, J. G., Green, G. M., Guan, D., McMahan, C. A. & Phillips, W. T. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 19, 468-471 (1996).
30. Choung, R. S. et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am. J. Gastroenterol. 107, 82-88 (2012).
31. Friedenberg, F. K., Kowalczyk, M. & Parkman, H. P. The influence of race on symptom severity and quality of life in gastroparesis. J. Clin. Gastroenterol. 47, 757-761 (2013).
32. Rayner, C. K. & Horowitz, M. New management approaches for gastroparesis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2, 454-462 (2005).
33. O'Grady, G. et al. Abnormal initiation and conduction of slow-wave activity in gastroparesis, defined by high-resolution electrical mapping. Gastroenterology 143, 589-598 e1-e3 (2012).
34. Vinik, A. I., Maser, R. E., Mitchell, B. D. & Freeman, R. Diabetic autonomic neuropathy. Diabetes Care 26, 1553-1579 (2003).
35. Chang, J. et al. A 25-year longitudinal evaluation of gastric emptying in diabetes. Diabetes Care 35, 2594-2596 (2012).
36. Chang, J., Rayner, C. K., Jones, K. L. & Horowitz, M. Prognosis of diabetic gastroparesis - a 25-year evaluation. Diabet. Med. 30, e185-e188 (2013).
37. Kong, M. F., Horowitz, M., Jones, K. L., Wishart, J. M. & Harding, P. E. Natural history of diabetic gastroparesis. Diabetes Care 22, 503-507 (1999).
38. Hyett, B. et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 137, 445-452 (2009).
39. Woerle, H. J. et al. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am. J. Physiol. Endocrinol. Metab. 294, E103-E109 (2008).
40. Woerle, H. J. et al. Pathways for glucose disposal after meal ingestion in humans. Am. J. Physiol. Endocrinol. Metab. 284, E716-E725 (2003).
41. Horowitz, M., Edelbroek, M. A., Wishart, J. M. & Straathof, J. W. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 36, 857-862 (1993).
42. Jones, K. L. et al. Gastric emptying in early noninsulin-dependent diabetes mellitus. J. Nucl. Med. 37, 1643-1648 (1996).
43. McIntyre, N., Holdsworth, C. D. & Turner, D. S. New interpretation of oral glucose tolerance. Lancet 2, 20-21 (1964).
44. Elrick, H., Stimmler, L., Hlad, C. J., Jr & Arai, Y. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 24, 1076-1082 (1964).
45. Kjems, L. L., Holst, J. J., Volund, A. & Madsbad, S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on -cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380-386 (2003).
46. Meier, J. J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728-742 (2012).
47. Ma, J. et al. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet. Med. 29, 604-608 (2012).
48. Pilichiewicz, A. N. et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am. J. Physiol. Endocrinol. Metab. 293, E743-E753 (2007).
49. O'Donovan, D. G. et al. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 3431-3435 (2004).
50. Trahair, L. G. et al. Effects of variations in duodenal glucose load on blood pressure, heart rate, superior mesenteric artery blood flow and plasma noradrenaline in healthy young and older subjects. Clin. Sci. (Lond.) 122, 271-279 (2012).
51. Marathe, C. S. et al. Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes. Diabetes 63, 2668-2675 (2014).
52. Thazhath, S. S., Wu, T., Young, R. L., Horowitz, M. & Rayner, C. K. Glucose absorption in small intestinal diseases. Expert Rev. Gastroenterol. Hepatol. 8, 301-312 (2014).
53. Corvilain, B. et al. Effect of short-term starvation on gastric emptying in humans: relationship to oral glucose tolerance. Am. J. Physiol. 269, G512-G517 (1995).
54. Horowitz, M., Cunningham, K. M., Wishart, J. M., Jones, K. L. & Read, N. W. The effect of short-term dietary supplementation with glucose on gastric emptying of glucose and fructose and oral glucose tolerance in normal subjects. Diabetologia 39, 481-486 (1996).
55. O'Donovan, D. et al. Effect of aging on transpyloric flow, gastric emptying, and intragastric distribution in healthy humans - impact on glycemia. Dig. Dis. Sci. 50, 671-676 (2005).
56. Schwartz, J. G., McMahan, C. A., Green, G. M. & Phillips, W. T. Gastric emptying in Mexican Americans compared to non-Hispanic whites. Dig. Dis. Sci. 40, 624-630 (1995).
57. Stevens, J. E. et al. Measurement of gastric emptying of a high-nutrient liquid by 3D ultrasonography in diabetic gastroparesis. Neurogastroenterol. Motil. 23, 220-e114 (2011).
58. Mourot, J. et al. Relationship between the rate of gastric emptying and glucose and insulin responses to starchy foods in young healthy adults. Am. J. Clin. Nutr. 48, 1035-1040 (1988).
59. Benini, L. et al. Gastric emptying of a solid meal is accelerated by the removal of dietary fibre naturally present in food. Gut 36, 825-830 (1995).
60. Brener, W., Hendrix, T. R. & McHugh, P. R. Regulation of the gastric emptying of glucose. Gastroenterology 85, 76-82 (1983).
61. Collins, P. J., Horowitz, M., Cook, D. J., Harding, P. E. & Shearman, D. J. Gastric emptying in normal subjects - a reproducible technique using a single scintillation camera and computer system. Gut 24, 1117-1125 (1983).
62. Ishii, M. et al. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 17, 901-903 (1994).
63. Gonlachanvit, S. et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig. Dis. Sci. 48, 488-497 (2003).
64. Vanis, L. et al. Effects of variations in intragastric volume on blood pressure and splanchnic blood flow during intraduodenal glucose infusion in healthy older subjects. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R391-R399 (2012).
65. Chaikomin, R. et al. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am. J. Physiol. Endocrinol. Metab. 289, E504-E507 (2005).
66. Unwin, N., Shaw, J., Zimmet, P. & Alberti, K. G. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med. 19, 708-723 (2002).
67. Abdul-Ghani, M. A., Williams, K., DeFronzo, R. A. & Stern, M. What is the best predictor of future type 2 diabetes? Diabetes Care 30, 1544-1548 (2007).
68. Phillips, W. T. Gastric emptying in ethnic populations: possible relationship to development of diabetes and metabolic syndrome. Ethn. Dis. 16, 682-692 (2006).
69. Duchman, S. M. et al. Upper limit for intestinal absorption of a dilute glucose solution in men at rest. Med. Sci. Sports Exerc. 29, 482-488 (1997).
70. Schirra, J. et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J. Clin. Invest. 97, 92-103 (1996).
71. Stevens, J. E. et al. Acute effects of C-peptide on gastric emptying in longstanding type 1 diabetes. Clin. Auton. Res. 16, 55-57 (2006).
72. Fraser, R. J. et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33, 675-680 (1990).
73. Russo, A. et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J. Clin. Endocrinol. Metab. 90, 4489-4495 (2005).
74. Schvarcz, E. et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 113, 60-66 (1997).
75. Kumar, A., Attaluri, A., Hashmi, S., Schulze, K. S. & Rao, S. S. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol. Motil. 20, 635-642 (2008).
76. Karamanolis, G., Caenepeel, P., Arts, J. & Tack, J. Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction? Gut 56, 29-36 (2007).
77. Sharma, D., Morrison, G., Joseph, F., Purewal, T. S. & Weston, P. J. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia 54, 2768-2770 (2011).
78. Kuo, P. et al. The nitric oxide synthase inhibitor, Ng-nitro-l-arginine-methyl-ester, attenuates the delay in gastric emptying induced by hyperglycaemia in healthy humans. Neurogastroenterol. Motil. 21, 1175-e103 (2009).
79. Vinik, A., Nakave, A. & Chuecos Mdel, P. A break in the brake mechanism in diabetes: a cause of postprandial hyperglycemia. Diabetes Care 31, 2410-2413 (2008).
80. Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653 (2005).
81. Gaber, A. O. et al. Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig. Dis. 9, 437-443 (1991).
82. Laway, B. A., Malik, T. S., Khan, S. H. & Rather, T. A. Prevalence of abnormal gastric emptying in asymptomatic women with newly detected diabetes and its reversibility after glycemic control - a prospective case control study. J. Diabetes Complications 27, 78-81 (2013).
83. Parkman, H. P. et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol. Motil. 22, 113-133 (2010).
84. Parkman, H. P. et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 140, 101-115 (2011).
85. Mashimo, H., Kjellin, A. & Goyal, R. K. Gastric stasis in neuronal nitric oxide synthase-deficient knockout mice. Gastroenterology 119, 766-773 (2000).
86. Watkins, C. C. et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J. Clin. Invest. 106, 373-384 (2000).
87. Takahashi, T., Nakamura, K., Itoh, H., Sima, A. A. & Owyang, C. Impaired expression of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology 113, 1535-1544 (1997).
88. Cellek, S., Foxwell, N. A. & Moncada, S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 52, 2353-2362 (2003).
89. Ordog, T., Takayama, I., Cheung, W. K., Ward, S. M. & Sanders, K. M. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 49, 1731-1739 (2000).
90. Tashima, K., Nishijima, M., Fujita, A., Kubomi, M. & Takeuchi, K. Acid secretory changes in streptozotocin-diabetic rats: different responses to various secretagogues. Dig. Dis. Sci. 45, 1352-1358 (2000).
91. Li, S. & Chen, J. D. Decreased L-type calcium current in antral smooth muscle cells of STZ-induced diabetic rats. Neurogastroenterol. Motil. 26, 971-979 (2014).
92. Choi, K. M. et al. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. Gastroenterology 138, 2399-2409.e1 (2010).
93. Kashyap, P. C. et al. Carbon monoxide reverses diabetic gastroparesis in NOD mice. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G1013-G1019 (2010).
94. Grover, M. et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 140, 1575-1585.e8 (2011).
95. Forster, J. et al. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J. Gastrointest. Surg. 9, 102-108 (2005).
96. He, C. L. et al. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 121, 427-434 (2001).
97. Iwasaki, H. et al. A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J. Gastroenterol. 41, 1076-1087 (2006).
98. Miller, S. M. et al. Distribution of interstitial cells of Cajal and nitrergic neurons in normal and diabetic human appendix. Neurogastroenterol. Motil. 20, 349-357 (2008).
99. Pasricha, P. J. et al. Changes in the gastric enteric nervous system and muscle: a case report on two patients with diabetic gastroparesis. BMC Gastroenterol. 8, 21 (2008).
100. Sokol, H., Lavergne-Slove, A., Mikol, J., Sabate, J. M. & Coffin, B. Severe isolated myopathic gastroparesis: a case report with pathological findings. Gut 55, 1662 (2006).
101. Grover, M. et al. Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol. Motil. 24, 531-539 (2012).
102. Faussone-Pellegrini, M. S. et al. Ultrastructural differences between diabetic and idiopathic gastroparesis. J. Cell. Mol. Med. 16, 1573-1581 (2012).
103. Emdin, M. et al. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 103, 513-519 (2001).
104. Guy, R. J. et al. Diabetic gastroparesis from autonomic neuropathy: surgical considerations and changes in vagus nerve morphology. J. Neurol. Neurosurg. Psychiatry 47, 686-691 (1984).
105. Feldman, M., Corbett, D. B., Ramsey, E. J., Walsh, J. H. & Richardson, C. T. Abnormal gastric function in longstanding, insulin-dependent diabetic patients. Gastroenterology 77, 12-17 (1979).
106. Kristensson, K., Nordborg, C., Olsson, Y. & Sourander, P. Changes in the vagus nerve in diabetes mellitus. Acta Pathol. Microbiol. Scand. A 79, 684-685 (1971).
107. Merio, R. et al. Slow gastric emptying in type I diabetes: relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care 20, 419-423 (1997).
108. Hasler, W. L. Gastroparesis: pathogenesis, diagnosis and management. Nat. Rev. Gastroenterol. Hepatol. 8, 438-453 (2011).
109. Owyang, C. Phenotypic switching in diabetic gastroparesis: mechanism directs therapy. Gastroenterology 141, 1134-1137 (2011).
110. Revicki, D. A. et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment. Pharmacol. Ther. 18, 141-150 (2003).
111. Revicki, D. A. et al. Development and content validity of a gastroparesis cardinal symptom index daily diary. Aliment. Pharmacol. Ther. 30, 670-680 (2009).
112. Reddymasu, S. C. & McCallum, R. W. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? J. Clin. Gastroenterol. 44, e8-e13 (2010).
113. George, N. S., Sankineni, A. & Parkman, H. P. Small intestinal bacterial overgrowth in gastroparesis. Dig. Dis. Sci. 59, 645-652 (2014).
114. Lysy, J., Israeli, E., Strauss-Liviatan, N. & Goldin, E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients. Neurogastroenterol. Motil. 18, 433-440 (2006).
115. Horowitz, M., Jones, K. L., Rayner, C. K. & Read, N. W. 'Gastric' hypoglycaemia management. Neurogastroenterol. Motil. 18, 405-407 (2006).
116. Hasler, W. L. Dumping Syndrome. Curr. Treat. Options Gastroenterol. 5, 139-145 (2002).
117. Shin, A. S. & Camilleri, M. Diagnostic assessment of diabetic gastroparesis. Diabetes 62, 2667-2673 (2013).
118. Bursztein-De Myttenaere, S. et al. Gastric emptying in humans: influence of different regimens of parenteral nutrition. Am. J. Clin. Nutr. 60, 244-248 (1994).
119. Abell, T. L. et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J. Nucl. Med. Technol. 36, 44-54 (2008).
120. Sachdeva, P. et al. Gastric emptying of solids and liquids for evaluation for gastroparesis. Dig. Dis. Sci. 56, 1138-1146 (2011).
121. Ziegler, D. et al. 13C octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 39, 823-830 (1996).
122. Viramontes, B. E. et al. Validation of a stable isotope gastric emptying test for normal, accelerated or delayed gastric emptying. Neurogastroenterol. Motil. 13, 567-574 (2001).
123. Rao, S. S. et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol. Motil. 23, 8-23 (2011).
124. Stein, E. et al. Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review. Agency for Healthcare Research and Quality [online] www.effectivehealthcare.ahrq.gov/reports/final.cfm (2013).
125. Kuo, B. et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment. Pharmacol. Ther. 27, 186-196 (2008).
126. Kunz, P. et al. Gastric emptying and motility: assessment with MR imaging - preliminary observations. Radiology 207, 33-40 (1998).
127. de Zwart, I. M. & de Roos, A. MRI for the evaluation of gastric physiology. Eur. Radiol. 20, 2609-2616 (2010).
128. Clements, J. A., Heading, R. C., Nimmo, W. S. & Prescott, L. F. Kinetics of acetaminophen absorption and gastric emptying in man. Clin. Pharmacol. Ther. 24, 420-431 (1978).
129. McCallum, R. W. et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 6, 463-467 (1983).
130. Ricci, D. A., Saltzman, M. B., Meyer, C., Callachan, C. & McCallum, R. W. Effect of metoclopramide in diabetic gastroparesis. J. Clin. Gastroenterol. 7, 25-32 (1985).
131. Wu, T. et al. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. Am. J. Clin. Nutr. 95, 78-83 (2012).
132. Ma, J. et al. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 32, 1600-1602 (2009).
133. Ma, J. et al. Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects. Br. J. Nutr. 104, 803-806 (2010).
134. Ma, J. et al. Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G735-G739 (2009).
135. Meier, J. J., Kemmeries, G., Holst, J. J. & Nauck, M. A. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54, 2212-2218 (2005).
136. Kolterman, O. G. et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 3082-3089 (2003).
137. Horowitz, M., Rayner, C. K. & Jones, K. L. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv. Ther. 30, 81-101 (2013).
138. Linnebjerg, H. et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 151, 123-129 (2008).
139. Deane, A. M. et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit. Care Med. 38, 1261-1269 (2010).
140. van Can., J. et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int. J. Obes. (Lond.) 38, 784-793 (2014).
141. Nauck, M. A., Kemmeries, G., Holst, J. J. & Meier, J. J. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60, 1561-1565 (2011).
142. Umapathysivam, M. M. et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like Peptide 1 receptor on gastric emptying and glycemia. Diabetes 63, 785-790 (2014).
143. Plummer, M. P. et al. Glucagon-like Peptide 1 attenuates the acceleration of gastric emptying induced by hypoglycemia in healthy subjects. Diabetes Care 37, 1509-1515 (2014).
144. Nonaka, T. et al. Early effect of single-dose sitagliptin administration on gastric emptying: crossover study using the 13C breath test. J. Neurogastroenterol. Motil. 19, 227-232 (2013).
145. Stevens, J. E. et al. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment. Pharmacol. Ther. 36, 379-390 (2012).
146. Vella, A. et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56, 1475-1480 (2007).
147. Aulinger, B. A. et al. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 63, 1079-1092 (2014).
148. Wu, T. et al. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans, and patients with type 2 diabetes treated with or without metformin. Diabetes 63, 2776-2787 (2014).
149. Samsom, M. et al. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G946-G951 (2000).
150. US Department of Health and Human Services US Food and Drug Administration [online] http://www.accessdata.fda.gov/drugsatfda-docs/nda/2005/21-332-Symlin.cfm (2005).
151. Ryan, G. J., Jobe, L. J. & Martin, R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin. Ther. 27, 1500-1512 (2005).
152. Wu, T. et al. Effects of a d-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. Diabetes Care 36, 1913-1918 (2013).
153. Nair, N. S. et al. Reproducibility of energy intake, gastric emptying, blood glucose, plasma insulin and cholecystokinin responses in healthy young males. Br. J. Nutr. 101, 1094-1102 (2009).
154. Hanefeld, M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc. Diabetol. 6, 20 (2007).
155. Cukier, K. et al. Effect of small intestinal glucose load on plasma ghrelin in healthy men. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295, R459-R462 (2008).
156. Parkman, H. P. et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 141, 486-498 (2011).
157. Patrick, A. & Epstein, O. Review article: gastroparesis. Aliment. Pharmacol. Ther. 27, 724-740 (2008).
158. Dishy, V. et al. The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis. Clin. Pharmacol. Ther. 76, 281-286 (2004).
159. Abell, T. L. et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol. Motil. 18, 263-283 (2006).
160. Camilleri, M. Clinical practice. Diabetic gastroparesis. N. Engl. J. Med. 356, 820-829 (2007).
161. Institute of Medicine. Dietary reference intakes: energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (National Academy Press, 2002).
162. Olausson, E. A. et al. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am. J. Gastroenterol. 109, 375-385 (2014).
163. Perkel, M. S., Moore, C., Hersh, T. & Davidson, E. D. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig. Dis. Sci. 24, 662-666 (1979).
164. Snape, W. J., Jr. et al. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann. Intern. Med. 96, 444-446 (1982).
165. Sugumar, A., Singh, A. & Pasricha, P. J. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin. Gastroenterol. Hepatol. 6, 726-733 (2008).
166. Sturm, A., Holtmann, G., Goebell, H. & Gerken, G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 60, 422-427 (1999).
167. Lartigue, S. et al. Inter-and intrasubject variability of solid and liquid gastric emptying parameters. A scintigraphic study in healthy subjects and diabetic patients. Dig. Dis. Sci. 39, 109-115 (1994).
168. Janssen, P. et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am. J. Gastroenterol. 108, 1382-1391 (2013).
169. Parkman, H. P., Carlson, M. R. & Gonyer, D. Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterol. Motil. 26, 521-528 (2014).
170. Simmons, K. & Parkman, H. P. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis. Dig. Dis. Sci. 59, 1231-1234 (2014).
171. Sawhney, M. S., Prakash, C., Lustman, P. J. & Clouse, R. E. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig. Dis. Sci. 52, 418-424 (2007).
172. Parkman, H. P. et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 310, 2640-2649 (2013).
173. Jones, K. L. et al. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 22, 339-344 (1999).
174. Horowitz, M., Jones, K. L., Harding, P. E. & Wishart, J. M. Relationship between the effects of cisapride on gastric emptying and plasma glucose concentrations in diabetic gastroparesis. Digestion 65, 41-46 (2002).
175. Pasricha, P. J., Pehlivanov, N., Sugumar, A. & Jankovic, J. Drug Insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 138-148 (2006).
176. Hasler, W. L. Emerging drugs for the treatment of gastroparesis. Expert Opin. Emerg. Drugs 19, 261-279 (2014).
177. Heddle, R., Fone, D., Dent, J. & Horowitz, M. Stimulation of pyloric motility by intraduodenal dextrose in normal subjects. Gut 29, 1349-1357 (1988).
178. Ezzeddine, D., Jit, R., Katz, N., Gopalswamy, N. & Bhutani, M. S. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest. Endosc. 55, 920-923 (2002).
179. Lacy, B. E., Crowell, M. D., Schettler-Duncan, A., Mathis, C. & Pasricha, P. J. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care 27, 2341-2347 (2004).
180. Lacy, B. E., Zayat, E. N., Crowell, M. D. & Schuster, M. M. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am. J. Gastroenterol. 97, 1548-1552 (2002).
181. Arts, J. et al. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment. Pharmacol. Ther. 24, 661-667 (2006).
182. Miller, L. S. et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am. J. Gastroenterol. 97, 1653-1660 (2002).
183. Ben-Youssef, R. et al. Intrapyloric injection of botulinum toxin a for the treatment of persistent gastroparesis following successful pancreas transplantation. Am. J. Transplant. 6, 214-218 (2006).
184. Bromer, M. Q. et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest. Endosc. 61, 833-839 (2005).
185. Kent, M. S. et al. A pilot study of botulinum toxin injection for the treatment of delayed gastric emptying following esophagectomy. Surg. Endosc. 21, 754-757 (2007).
186. Wiesel, P. H. et al. Botulinum toxin for refractory postoperative pyloric spasm. Endoscopy 29, 132 (1997).
187. Arts, J. et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment. Pharmacol. Ther. 26, 1251-1258 (2007).
188. Friedenberg, F. K., Palit, A., Parkman, H. P., Hanlon, A. & Nelson, D. B. Botulinum toxin A for the treatment of delayed gastric emptying. Am. J. Gastroenterol. 103, 416-423 (2008).
189. McCallum, R. W. et al. Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin. Gastroenterol. Hepatol. 9, 314-319 (2011).
190. Lin, Z., Sarosiek, I., Forster, J. & McCallum, R. W. Symptom responses, long-term outcomes and adverse events beyond 3 years of high-frequency gastric electrical stimulation for gastroparesis. Neurogastroenterol. Motil. 18, 18-27 (2006).
191. Anand, C. et al. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers. Digestion 75, 83-89 (2007).
192. Abell, T. et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 125, 421-428 (2003).
193. Jones, M. P. Gastric electrical stimulation for refractory gastroparesis. Gastroenterology 126, 629-630 (2004).
194. Ayinala, S. et al. Temporary gastric electrical stimulation with orally or PEG-placed electrodes in patients with drug refractory gastroparesis. Gastrointest. Endosc. 61, 455-461 (2005).
195. Toro, J. P. et al. Efficacy of laparoscopic pyloroplasty for the treatment of gastroparesis. J. Am. Coll. Surg. 218, 652-660 (2014).
196. Kashyap, P. & Farrugia, G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut 59, 1716-1726 (2010).
197. Ray, W. A. et al. Oral erythromycin and the risk of sudden death from cardiac causes. N. Engl. J. Med. 351, 1089-1096 (2004).
198. Javid, F. A. et al. Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors. Eur. J. Pharmacol. 699, 48-54 (2013).
199. Straus, S. M. et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur. Heart J. 26, 2007-2012 (2005).
200. Larson, J. M., Tavakkoli, A., Drane, W. E., Toskes, P. P. & Moshiree, B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J. Neurogastroenterol. Motil. 16, 407-413 (2010).
201. McCallum, R. W., Cynshi, O. & Investigative Team. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. Aliment. Pharmacol. Ther. 26, 1121-1130 (2007).
202. Camilleri, M. Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. J. Clin. Invest. 123, 4111-4120 (2013).
203. Ejskjaer, N. et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment. Pharmacol. Ther. 29, 1179-1187 (2009).
204. Ejskjaer, N. et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol. Motil. 22, 1069-e281 (2010).
205. Shin, A. et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 36, 41-48 (2013).
206. Shin, A. et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin. Gastroenterol. Hepatol. 11, 1453-1459 (2013).
207. Kusunoki, H. et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol. Motil. 24, 540-545, e250-e251 (2012).
208. Tack, J., Janssen, P., Masaoka, T., Farre, R. & Van Oudenhove, L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin. Gastroenterol. Hepatol. 10, 1239-1245 (2012).